Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,307 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
Regulatory Filings Classification · 92% confidence The document is a company announcement (“Selskabsmeddelelse”) disclosing that Bavarian Nordic has received a new government contract for vaccines. It contains no financial statements or earnings data, no capital raising, no board changes, votes, dividends, or calls. It is a standard regulatory announcement under the EU market abuse regulation for disclosure of inside information. This fits the general regulatory announcement category, RNS, as a fallback for miscellaneous filings that are not covered by other specific categories.
2026-06-09 Danish
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing that Bavarian Nordic has received a new government contract order for its mpox/smallpox vaccine. It does not constitute a financial report, debt/equity financing update, or other specialized filing (like earnings release or management changes), but is a general regulatory announcement of company news. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-06-09 Danish
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
Regulatory Filings Classification · 86% confidence The document is a public company announcement/disclosure of inside information under the EU Market Abuse Regulation describing a government contract award. It does not contain financial statements, earnings release data, board or management changes, dividends, or proxy materials. It is not a full report but a regulatory announcement of material information. Therefore it falls into the fallback category of Regulatory Filings (RNS).
2026-06-09 English
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Bavarian Nordic has secured a government vaccine supply contract, including forward-looking statements and inside information disclosures under the EU Market Abuse Regulation. It does not present financial statements (ruling out 10-K, IR, ER, etc.), nor is it a meeting material, proxy, dividend notice, or similar. It is a general regulatory announcement and falls into the fallback category of Regulatory Filings (RNS).
2026-06-09 English
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Transaction in Own Shares Classification · 96% confidence The document is an appendix to a company announcement detailing actual transactions under a share buyback program for specific dates, including quantities, prices, venues, and times. It is not announcing a report publication but provides the granular transaction data of the company buying its own shares. This fits the definition of a “Transaction in Own Shares” (POS).
2026-06-08 Danish
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Transaction in Own Shares Classification · 91% confidence The document is a company announcement (‘Selskabsmeddelelse’) disclosing actual share repurchase transactions under an authorized buyback program, including dates, quantities, average prices and aggregate totals. This type of announcement detailing the company’s own share transactions fits the category “Transaction in Own Shares” (POS) rather than a share issue or dividend notice. It is not a request for votes, regulatory filing, or other report type; it specifically reports on buybacks of its own shares.
2026-06-08 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.